NCT00316849 arm group 07c74498ec724bf3ff4108cfdac4ff70 [clinicaltrials_resource:NCT00316849/arm-group/07c74498ec724bf3ff4108cfdac4ff70]
3-dimensional conformal radiation therapy [clinicaltrials_resource:08b22300f61bffec575572a3d66cb0fa]temozolomide [clinicaltrials_resource:216d8e095d4ce38421a6af01f340b1b1]intensity-modulated radiation therapy [clinicaltrials_resource:4c14269c9bab859c1c076e041d11035d]adjuvant therapy [clinicaltrials_resource:56c84579a1e40856824bcd0c6a692ba9]pharmacological study [clinicaltrials_resource:a3d8a6083c5b8c394fd9c18c5c4226eb]temsirolimus [clinicaltrials_resource:aec46dd2afba1f6ebe10153a72a7a42a]Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme [clinicaltrials:NCT00316849]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00316849 arm group 07c74498ec724bf3ff4108cfdac4ff70 [clinicaltrials_resource:NCT00316849/arm-group/07c74498ec724bf3ff4108cfdac4ff70]
Bio2RDF identifier
NCT00316849/arm-group/07c74498ec724bf3ff4108cfdac4ff70
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... c74498ec724bf3ff4108cfdac4ff70
description [clinicaltrials_vocabulary:description]
GROUP 1: (temsirolimus with ra ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:NCT00316849/arm-group/07c74498ec724bf3ff4108cfdac4ff70
title
NCT00316849 arm group 07c74498ec724bf3ff4108cfdac4ff70
@en
type
label
NCT00316849 arm group 07c74498 ...... 74498ec724bf3ff4108cfdac4ff70]
@en